hypoglycaemia
Treat diabetic hypoglycaemia immediately (15 g fast-acting carb for Level 1–2; 20 g PO, glucagon 3 mg IN / 1 mg SC–IM, or D50W 10–25 g IV for Level 3). Enforce “5 to drive” (≥4.0 to drive, wait 40 min after recovery to ≥5.0). In patients without diabetes, investigate only if Whipple’s triad is documented — draw insulin, C-peptide, proinsulin, β-hydroxybutyrate, and sulfonylurea screen at the time of hypoglycaemia (<3.0 mmol/L).
Sulfonylurea overdose / accumulation (especially glyburide in CKD): hypoglycaemia recurs for 24–72 h after a single dextrose bolus → admit, infuse dextrose, and give octreotide if refractory (dextrose alone triggers further endogenous insulin release). Also never miss adrenal insufficiency, sepsis, liver failure, or surreptitious insulin in an unexplained severe low.
acute management in diabetes
| level | definition | immediate treatment | follow-up |
|---|---|---|---|
| Level 1 | BG 3.0–3.9 mmol/L (alert) | 15 g fast-acting carb (glucose tabs, 150 mL juice/regular pop, 15 mL honey); 5–10 g if on AID pump | recheck in 15 min; repeat 15 g if still <3.9 mmol/L |
| Level 2 | BG <3.0 mmol/L (clinically significant) | same as Level 1 (15 g fast-acting carb; avoid glucose gel — too slow) | recheck in 15 min; follow with usual meal or snack (15 g carb + protein) if meal >1 h away |
| Level 3 (conscious, can swallow) | severe neuroglycopenia requiring external assistance | 20 g oral glucose OR glucagon 3 mg IN (Baqsimi) / 1 mg SC or IM | recheck in 15 min; repeat 15 g if <3.9 |
| Level 3 (unconscious / unsafe swallow) | — | no IV: glucagon 3 mg IN or 1 mg SC/IM · IV access: 10–25 g IV glucose (20–50 mL D50W over 1–3 min) | call EMS / reassess; give meal or IV dextrose once awake (glucagon effect lasts <2 h and fails in hepatic glycogen depletion / alcohol) |
- Impaired awareness of hypoglycaemia (IAH): defective counter-regulation from recurrent antecedent lows (HAAF). Management = 2–3 weeks (up to 3 months) of scrupulous hypoglycaemia avoidance with relaxed targets, rtCGM (Grade A in T1DM / Grade B in T2DM for unrecognised hypoglycaemia; Grade B for CSII/CGM/SAP in T1DM with IAH/level 3), AID in T1DM, and switching from NPH/first-generation basal to degludec or glargine U-300 (and stopping sulfonylureas).
- Ontario: Intranasal glucagon (Baqsimi) is ODB-covered via LU 625 for insulin-treated patients at high risk for severe hypoglycaemia.
driving rules (DC & CMA)
Applies to drivers treated with insulin or insulin secretagogues:
- Before and during driving: carry fast-acting carbs within reach; check BG immediately before driving and every 4 hours (every 2 hours if IAH or severe hypoglycaemia in the past 12 months) — or wear rtCGM.
- “5 to drive”: do not drive if BG <4.0 mmol/L. If <4.0, treat and wait at least 40 minutes after BG reaches ≥5.0 mmol/L before driving (cognitive recovery lags behind normoglycaemia).
- Driving cessation & provincial reporting to licensing authority (physician reporting is mandatory in most provinces including Ontario for prescribed conditions, discretionary in AB/NS/QC, and conditional in BC if the driver continues despite warning):
- 1 episode of severe hypoglycaemia while driving in the past 12 months (private or commercial) — stop driving immediately and notify clinician within 72 hours.
- Awake severe hypoglycaemia (not driving): >1 episode in the past 6 months (private) or 12 months (commercial, DC 2018); note CMA 2023 is stricter for insulin-treated commercial drivers — any episode of severe awake hypoglycaemia or hypoglycaemia unawareness in the past 6 months disqualifies commercial driving (reinstatement after 6 months free of both).
non-diabetic hypoglycaemia workup
Evaluate only when Whipple’s triad is established: (1) compatible symptoms/signs, (2) venous plasma glucose <3.0 mmol/L (capillary meters are inaccurate in the low range), and (3) symptom resolution when glucose is raised.
- First assess clinical context (ill/medicated patient): drugs (insulin, secretagogues, alcohol, fluoroquinolones, pentamidine, quinine, tramadol, β-blockers masking symptoms), hepatic/renal/cardiac failure, sepsis, inanition, cortisol deficiency (adrenal insufficiency), non-islet cell tumour (IGF-2).
- Seemingly well patient → test during a spontaneous episode, or perform a supervised 72-hour fast (or 5-hour mixed-meal test if purely postprandial; never use an OGTT).
- During the 72-hour fast, sample glucose/insulin/C-peptide/proinsulin/BHB q6h until BG <3.3 mmol/L, then q1–2h. End the fast when BG ≤2.5 mmol/L with symptoms (or <3.0 with Whipple’s triad already documented), draw the critical sample + oral hypoglycaemic screen, then give glucagon 1 mg IV and measure glucose at 10, 20, and 30 min (≥2/3 of insulinomas trigger within 24 h; almost all by 48 h).
interpreting the critical sample (venous glucose <3.0 mmol/L)
| diagnosis | insulin (pmol/L) | proinsulin (pmol/L) | C-peptide (nmol/L) | BHB (mmol/L) | Δ glucose after 1 mg IV glucagon | SU / meglitinide screen | insulin Ab |
|---|---|---|---|---|---|---|---|
| normal / non-insulin-mediated (starvation, organ failure, AI) | <18 | <5 | <0.2 | >2.7 | <1.4 mmol/L | neg | neg |
| exogenous insulin | ≥18 (often >>18) | <5 | <0.2 | ≤2.7 | ≥1.4 mmol/L | neg | neg/pos |
| insulinoma / NIPHS / post-bariatric | ≥18 | ≥5 | ≥0.2 | ≤2.7 | ≥1.4 mmol/L | neg | neg |
| sulfonylurea / meglitinide | ≥18 | ≥5 | ≥0.2 | ≤2.7 | ≥1.4 mmol/L | positive | neg |
| insulin autoimmune syndrome | >>18 | ≥5 | ≥0.2 | ≤2.7 | ≥1.4 mmol/L | neg | positive |
| IGF-2 (non-islet cell tumour) | <18 | <5 | <0.2 | ≤2.7 | ≥1.4 mmol/L | neg | neg |
Endogenous or exogenous insulin (and IGF-2) blocks ketogenesis (so BHB stays ≤2.7 mmol/L despite hypoglycaemia) and preserves hepatic glycogen (so IV glucagon raises BG ≥1.4 mmol/L). C-peptide separates exogenous insulin (low) from endogenous hyperinsulinism (high); the oral secretagogue screen separates sulfonylurea use from insulinoma.
- Insulinoma: once endogenous hyperinsulinism is confirmed (and secretagogue screen negative), localise with multiphasic CT/MRI ± endoscopic ultrasound (do not image before biochemical confirmation). Screen for MEN1 if young, multifocal, or family history. Medical bridge: diazoxide or octreotide.
- Post-bariatric hypoglycaemia: typically postprandial (1–3 h after high-carb meals, >1 year post-Roux-en-Y bypass); diagnose with mixed-meal test; first-line treatment = low-glycaemic-index small frequent meals with protein/fat, then acarbose, diazoxide, or octreotide.
Prepared 2026-11-19. Not yet verified — check every number against the sources.